US patent for Acusphere contrast agents
This article was originally published in Clinica
Acusphere has received a US patent relating to its gas-filled microspheres for use in enhancing ultrasound contrast agents. The patent covers the company's method of making the high-porosity (hollow) microspheres which have the low porosity outer shell from synthetic polymers. While an increased internal porosity allows the microspheres to hold more gas, thus improving the contrast agent's effectiveness, a low porosity of the external shell prevents the gas from leaking out of the micro-particle, said the company of Cambridge, Massachusetts. Acusphere has also started a US Phase I clinical trial to test its lead contrast agent, AI-700, as a means of assessing myocardial perfusion.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.